Table 2 Treatment duration and dose modifications
From: FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience
Cycles | Number |
|---|---|
Median | 6 |
Range | 1–31 |
>3 | 77 |
3 | 4 |
2 | 9 |
1 | 12 |
Dose modifications | n (%) |
Started with full dose of all drugs | 33 (32.4) |
Started with reduced dose of 1 or more drugs | 69 (67.6) |
Reduction or omission of 5-FU bolus | 93% |
Reduction in irinotecan | 88% |
Reduction in oxaliplatin | 68% |
Reduction infusional 5-FU | 66% |
